Two years post-stealth exit, highly secretive inflammation biotech secures final tranche of Series A round
Back in September 2020, a tiny biotech emerged from stealth out of Nashville, calling itself Amytrx Therapeutics and pursuing chronic inflammation. By all measures, the biotech has been extremely quiet — publishing only one press release announcing its stealth exit.
Now, it’s got its next one.
The biotech announced Wednesday that it closed the final tranche of its Series A round, which totals $18 million to expand on clinical research for AMTX-100, its anti-inflammatory peptide drug candidate that is being researched for a variety of inflammatory indications.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.